About Genomind
Genomind is a company based in King Of Prussia (United States) founded in 2009. Genomind has raised $64.43 million across 7 funding rounds from investors including SVB, HHS and Claritas Capital. Genomind operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter King Of Prussia, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genomind, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$64.43 M (USD)
in 7 rounds
-
Latest Funding Round
$399.59 K (USD), Grant
Sep 21, 2023
-
Investors
SVB
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Genomind
Unlock access to complete
Unlock access to complete
Funding Insights of Genomind
Genomind has successfully raised a total of $64.43M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $399.59 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genomind
Genomind has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, HHS and Claritas Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to early-stage real estate projects.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Banking services are provided to innovative companies, investors, and individuals.
|
Locked | Locked | Locked |
Investor details for Genomind
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomind
Investment portfolio details for Genomind
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genomind
Detailed financials for Genomind
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomind Comparisons
Peer comparison for Genomind
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genomind
Genomind operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Genomind
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomind
Complete news archive for Genomind
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomind
Genomind was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Genomind is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
Bill Brown is the current CEO of Genomind.
Genomind is a funded company, having raised a total of $64.43M across 7 funding rounds to date.
Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genominds PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.
Genomind's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Genomind has 3 investors. Key investors include SVB, HHS, and Claritas Capital.